

## Sylvie Dupont

---

**From:** Tim, Emmelia (TOR) [etim@Express-Scripts.com]  
**Sent:** Thursday, May 05, 2005 12:08 PM  
**To:** Sylvie Dupont  
**Subject:** Response to Discussion Paper on the issue of drug price increases

To Whom it May Concern,

This is in regards to your request for feedback on the discussion paper for Price Increases for Patented Medicines:

ESI Canada, a Pharmacy Benefit Management company that adjudicates drug claims on behalf of private insurers would like to see Framework 3 implemented. Increases that are currently made without review or notification puts the private insurers at risk for having to pay more than they should. In addition, without prior notification of the intended increase, private insurers are ill-prepared to cover the increasing costs of medications. In addition, when pharmaceutical companies are asked to pay back the excessive amount to the Government of Canada, the private insurers are not justly compensated for the over-payments that they have made for the drugs. Instead of the excess revenues being paid to the Government of Canada, it is suggested that prices of other brand drugs within the pharmaceutical company's portfolio be reduced to offset the excess revenues, as the main avenue to compensate the appropriate payers.

Thank you for giving us the chance to provide our feedback.

Kind Regards,

**Emmelia**

Emmelia Tim, B.Sc.Pharm  
Manager, Clinical Services  
ESI Canada  
5770 Hurontario St.  
Mississauga, Ontario  
L5R 3G5  
Tel: 905-712-8615 ext2310  
E-mail: etim@express-scripts.com

---

\*\*\*\*\* Confidentiality Notice \*\*\*\*\*

*This email, its electronic document attachments, and the contents of its website linkages may contain confidential health information. This information is intended solely for use by the individual or entity to whom it is addressed. If you have received this information in error, please notify the sender immediately and arrange for the prompt destruction of the material and any accompanying attachments.*